Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 13/20 | 0.42 |
| ▸ | CDK9 | P50750 | 13/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24493330 | 0.89 | CCNT1 (0.39) | CCNT1CDK9APAF1CASP3SENP8 | |
| SCHEMBL30578277 | 0.89 | CCNT1 (0.39) | CCNT1CDK9APAF1CASP3SENP8 | |
| SCHEMBL24493331 | 0.89 | CCNT1 (0.39) | CCNT1CDK9APAF1CASP3SENP8 | |
| SCHEMBL24493315 | 0.84 | MRGPRX1 (0.47) | CCNT1CDK9ROCK2ROCK1 | |
| SCHEMBL30578216 | 0.84 | MRGPRX1 (0.47) | CCNT1CDK9ROCK2ROCK1 | |
| SCHEMBL24493569 | 0.79 | KDR (0.39) | CCNT1CDK9EGFR | |
| SCHEMBL29119690 | 0.79 | GRM4 (0.41) | CCNT1CDK9 | |
| SCHEMBL30578248 | 0.79 | KDR (0.39) | CCNT1CDK9EGFR | |
| SCHEMBL29650050 | 0.79 | KDR (0.39) | CCNT1CDK9EGFR | |
| SCHEMBL24493583 | 0.78 | HRH3 (0.40) | APAF1CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059691-A1 | ENZYME INHIBITORS | SERPINB1, XDH, ACE | CCNT1 644/4885CDK9 499/4885APAF1 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.